Masimo Taps Katie Szyman

Masimo Taps Katie Szyman as Permanent CEO
Masimo appointed Katie Szyman as its next chief executive officer after a proxy fight forced out the company’s founder. Szyman will become CEO of the medical-device maker Feb. 12, replacing interim CEO Michelle Brennan.
Masimo taps Becton Dickinson executive Katie Szyman as CEO (Jan. 21)
(This Jan. 21 story has been corrected to fix the share price gain to 57% from 45% in paragraph 6) (Reuters) - Masimo named Becton Dickinson executive Katie Szyman as its top boss, the medical device maker said on Tuesday,
Masimo picks Katie Szyman as CEO
Szyman led Edwards Lifesciences’ critical care unit for more than a decade before BD acquired the group last year. Her appointment “fits like a glove,” BTIG analyst Marie Thibault wrote.
Masimo names former Edwards Critical Care leader Katie Szyman as next CEO
Masimo (Nasdaq: MASI) + Masimo Corporation $172.4 1.44% Open 173.198 Day High 175.067 52 Week High 147.89 52 Week Low 75.22 announced today that it appointed Katie Szyman as its new CEO, effective Feb. 12, 2025.
Masimo names med-tech vet Katie Szyman CEO
Szyman, an industry leader with deep med-tech roots, to guide the company as it seeks to rebuild its reputation and revenues following a gritty two-year battle for control. Current CEO Michelle Brennan will serve as chairman of the Masimo board.
Masimo Appoints Katie Szyman as Permanent CEO
Masimo Corp. today announced Katie Szyman as its new chief executive, effective Feb. 12. Szyman is currently worldwide president of BD Advanced Patient Monitoring, the former Critical Care unit of Edwards Lifesciences Corp. that was acquired by Becton, Dickinson and Co. last year for $4.2 billion.
Masimo names Katie Szyman CEO
Masimo (MASI) announced that Katie Szyman has been appointed the next Chief Executive Officer of the Company. Interim CEO Michelle Brennan has
Masimo names Becton Dickinson's Katie Szyman CEO
Masimo said on Tuesday it has named Becton Dickinson executive Katie Szyman as chief executive officer after a bitter proxy battle with activist hedge fund Politan Capital Management led to the ouster of founder Joe Kiani from the medical device maker's board last year.
FierceBiotech1d
Masimo lands new CEO from BD's patient monitoring division
After its longtime chief was ousted last year following a proxy battle, Masimo has now appointed a new CEO. | The medtech has ...
Needham & Company LLC Reiterates “Hold” Rating for Masimo (NASDAQ:MASI)
Masimo (NASDAQ:MASI – Get Free Report)‘s stock had its “hold” rating reaffirmed by equities research analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports.
Business Wire2d
Masimo Announces Leadership Transition
Today the Board of Directors (the “Board”) of Masimo (NASDAQ: MASI), a leading global medical innovator, announced that Katie Szyman has been appointe ...
BTIG Remains a Buy on Masimo (MASI)
BTIG analyst Marie Thibault reiterated a Buy rating on Masimo (MASI – Research Report) today and set a price target of $178.00. The company’s ...
MassDevice7d
Masimo expects healthcare sales to grow around 10% in 2025
Looking ahead to 2025, Masimo projects healthcare revenues to land between $1.5 billion and $1.53 billion. That would deliver ...
Masimo Stock Gains Following Solid Preliminary Q4 Revenues
MASI's revenue growth in the fourth quarter is likely to have been boosted by the continued robust adoption of its products.
Cautious Optimism Amid Leadership Change and Strategic Uncertainty at Masimo
Needham analyst Michael Matson has maintained their neutral stance on MASI stock, giving a Hold rating on January 17.Invest with Confidence: ...